ProfileGDS5678 / 1417598_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 93% 94% 93% 91% 93% 95% 94% 94% 94% 93% 94% 93% 93% 94% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.8389493
GSM967853U87-EV human glioblastoma xenograft - Control 28.203694
GSM967854U87-EV human glioblastoma xenograft - Control 37.9598293
GSM967855U87-EV human glioblastoma xenograft - Control 47.6711291
GSM967856U87-EV human glioblastoma xenograft - Control 57.9949193
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 18.1960295
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 28.0457794
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 38.0838994
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 48.1489294
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.9189693
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.9731694
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 38.0117793
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.8487293
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 58.1044294